Illimis Therapeutics Revenue

Biotechnology Research • 18, Heolleung-ro 569-gil, Korea, Republic of • 21-50 Employees

Illimis Therapeutics revenue & valuation

Annual revenue	$2,053,320
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$6,600,000
Total funding	$57,200,000

Key Contacts at Illimis Therapeutics

Sanghoon Park

Co-Founder & Ceo

Suchul Jang

Chief Executive Officer Of Illimis Therapeutics Usa

Eun-Jung Lee

Director, Discovery Group

Company overview

Headquarters	18, Heolleung-ro 569-gil, Gangnam-gu, Seoul, 06376, KR
Phone number	+828368801987
Website	illimistx.com
NAICS	541714
Founded	2021
Employees	21-50
Socials

Illimis Therapeutics Email Formats

Illimis Therapeutics uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@illimistx.com), used 80% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@illimistx.com	80%
{first name}{last name}	johndoe@illimistx.com	20%

About Illimis Therapeutics

Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimer’s. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from existing antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells.

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Manager

Entry

C-Suite

Employees by Department

Illimis Therapeutics has 6 employees across 5 departments.

Departments

Number of employees

Funding Data

Explore Illimis Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount
2023-02-01	1	N/A
2023-05-06	4	$15,200,000
2025-08-14	5	$42,000,000

Funding Insights

$57,200,000

Total funding amount

$42,000,000

Most recent funding amount

Number of funding rounds

Illimis Therapeutics Tech Stack

Discover the technologies and tools that power Illimis Therapeutics's digital infrastructure, from frameworks to analytics platforms.

Cloudflare

CDN

Apache HTTP Server

Web servers

jQuery CDN

CDN

Naver Analytics

Analytics

jQuery

JavaScript libraries

Google Tag Manager

Tag managers

PHP

Programming languages

Open Graph

Miscellaneous

Sectigo

SSL/TLS certificate authorities

Swiper

JavaScript libraries

Google Analytics

Analytics

jQuery UI

JavaScript libraries

Frequently asked questions

Illimis Therapeutics is located in 18, Heolleung-ro 569-gil, KR.

You can reach Illimis Therapeutics at +828368801987.

Illimis Therapeutics generates an estimated annual revenue of $2,053,320. This revenue figure reflects the company's market position and business performance in its industry.

Illimis Therapeutics has an estimated valuation of $6,600,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Illimis Therapeutics was founded in 2021, making it 5 years old. The company has established itself as a significant player in its industry over this time.

Illimis Therapeutics has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

Illimis Therapeutics has raised a total of $57,200,000 across 3 funding rounds. This investment has helped the company grow and expand its operations.

Key Contacts at Illimis Therapeutics

Sanghoon Park

Co-Founder & Ceo

Suchul Jang

Chief Executive Officer Of Illimis Therapeutics Usa

Eun-Jung Lee

Director, Discovery Group

4.8

40,000 users